The NM_003494.4: c.206T>G variant in DYSF, which is also known as NM_001130987.2: c.209T>G p.(Val70Gly), is a missense variant predicted to cause substitution of valine to glycine at amino acid 69, p.(Val69Gly). This variant has been reported in at least four patients with suspected LGMD (PMID: 33250842, 35723113, 39925440), including in a homozygous state in two individuals without known familial consanguinity (1 pt; PMID: 33250842, 35723113) and in unknown phase with a pathogenic variant in one individual (NM_003494.4: c.5668-824C>T, 0.5 pts, PMID: 39925440) (PM3). At least one of the patients with a second presumed diagnostic DYSF variant displayed progressive muscle weakness and absent dysferlin expression in muscle biopsy, which is highly specific for DYSF-related LGMD (PMID: 33250842) (PP4_Strong). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). Immunofluorescence and 2-A assays of dysferlin membrane localization in HEK293T cells showed the Val69Gly protein did not reach the cell membrane, indicating an impact on protein function (PMID: 35028538) (PS3_Moderate). In addition, the computational predictor REVEL gives a score of 0.83, which is above the LGMD VCEP threshold of ≥0.70, evidence that correlates with impact to DYSF function (PP3). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 1.0.0; 07/29/2025): PM3, PP4_Strong, PM2_Supporting, PS3_Moderate, PP3.